Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OAT | P04181 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218786 | 1.00 | GABRR1 (0.36) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL14439278 | 1.00 | GABRR1 (0.36) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL21757620 | 1.00 | GABRR1 (0.36) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL29550605 | 0.83 | GABRR1 (0.42) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL20363529 | 0.82 | GABRR1 (0.33) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL416062 | 0.82 | GABRR1 (0.33) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL17453292 | 0.79 | GABRR1 (0.32) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL419019 | 0.70 | GABRR1 (0.36) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL12929618 | 0.70 | GABRR1 (0.36) | GABRR1TSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL19215291 | 0.68 | NOS3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10385367-B2 | Methods and molecules for yield improvement involving metabolic engineering | GINKGO BIOWORKS, INC. | 2019-08-20 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10337034-B2 | Biomass conversion to fuels and chemicals | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20130252294-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-09-26 | — | — | US | disclosed |
| US-20130252294-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-09-26 | — | — | US | disclosed |
| US-20130252294-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2013-09-26 | — | — | US | disclosed |
| WO-2012106257-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196339-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | LOS ALAMOS NATIONAL SECURITY LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196339-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | LOS ALAMOS NATIONAL SECURITY LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120196339-A1 | PRODUCTION OF INDUSTRIALLY RELEVANT COMPOUNDS IN PROKARYOTIC ORGANISMS | LOS ALAMOS NATIONAL SECURITY LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120070870-A1 | Methods and Molecules for Yield Improvement Involving Metabolic Engineering | GINKGO BIOWORKS (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070870-A1 | Methods and Molecules for Yield Improvement Involving Metabolic Engineering | GINKGO BIOWORKS (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2010141468-A1 | METHODS AND MOLECULES FOR YIELD IMPROVEMENT INVOLVING METABOLIC ENGINEERING | WAY JEFFREY C (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10337034-B2 | Biomass conversion to fuels and chemicals | ALG1, MGAM, ME1 | GABRR1 2719/4885TSHR 4723/4885MAPK1 3203/4885 |
| US-10385367-B2 | Methods and molecules for yield improvement involving metabolic engineering | COASY, TALDO1, MRPL21 | GABRR1 3380/4885TSHR 4133/4885MAPK1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.